Glucan-based macrophage stimulators a review of their anti-infective potential

Clinical Immunotherapeutics

Volumn 5, Issue 5, 1996, Pages 392-399

  Williams, Davidl ^a   Mueller, Antje ^a   Erowder, William ^a  

^a East Tennessee State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUCAN;

DRUG MECHANISM; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOPROPHYLAXIS; MACROPHAGE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTICEMIA; SURGICAL PATIENT;

EID: 0029977686     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259335     Document Type: Article

References (50)

1. Bone RC. Gram-negative sepsis. Background, clinical features and intervention. Chest 1991; 100: 802-8
2. Welbourn CR, Young Y. Endotoxin, septic shock and acute lung injury: neutrophils, macrophages and inflammatory mediators. Br J Surg 1992; 79: 998-1003
3. Ertel W, Morrison MH, Wang P, et al. The complex pattern of cytokines in sepsis. Association between prostaglandins. cachectin and interleukins. Ann Surg 1991; 214: 141-8
4. Scatter SC, Bennet T. Li MH, et al. Macrophage endotoxin tolerance: tumor necrosis factor and interleukin-1 regulation by lipopolysaccharide pretreatment. Arch Surg 1994; 129: 1263-70
5. Ayala A, Perrin MM, Wang P, et al. Sepsis induces an early increased spontaneous release of hepatocellular stimulatory factor (interleukin-6) by Kupt'fer cells in both endotoxin tolerant and intolerant mice. J Surg Res 1992; 52: 635-41
6. Ayala A, Perrin MM, Kidala JM, et al. Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (interleukin-l and -6) and tumor necrosis factor. Circ Shock 1992; 36: 191-9
7. Natanson C. Hoffman WD, Suffredini AF, et al. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120; 771-83
8. McCloskey RV, Sträube RC, Sanders C. et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group |see comments]. Ann Intern Med 1994; 121: 1-5
9. Zanetti G, Glauser MP, Baumgartner JD. Anti-endotoxin antibodies and other inhibitors of endotoxin. New Horizons 1993; I: 110-9
10. Fisher JrCJ, Dhainaut JF, Opal SM. étal. Recombinant human interleukin I receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, doubleblind, placebo-controlled trial. Phase III rhlL-lra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-43
11. Dries DJ, Jurkovick GJ, Maier RV, et al. Effect of interferon gamma on infection-related death in patients with severe injuries: a randomized, double-blind, placebo-controlled trial. Arch Surg 1994; 129: 1031-41
12. Browder W, Williams D, Pretus H, et al. Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg 1990; 211: 605-13
13. Babineau TJ, Marcello P, Swails W, et al. Randomized phase l/II trial of a macrophage-specific immunomodulator (PGGglucan) in high-risk surgical patients. Ann Surg 1994; 220: 601-9
14. Babineau TJ, Hackford A, Kenler A, et al. A phase II multicenter. double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (pgg-glucan) in highrisk surgical patients. Arch Surg 1994; 129: 1204-10
15. Williams DL, Browder IW, DiLuzio NR. Immunotherapeutic modification of Escherk'hia coli-induced experimental peritonitis and bacteremia by glucan. Surgery 1983; 93: 448-54
16. Browder W, Williams D, Sherwood E, et al. Synergistic effect of nonspecific immunostimulation and antibiotics in experimental peritonitis. Surgery 1987; 102: 206-14
17. Moore JN, Cook JA, Morris DD, et al. Endotoxin-induced procoagulant activity, eicosanoid synthesis, and tumor necrosis factor production by rat peritoneal macrophages: effect of endotoxin tolerance and glucan. Circ Shock 1990; 31: 281 -95
18. Sherwood ER, Williams DL, McNamee RB, et al. Enhancement of interleukin-l and interleukin-2 production by soluble glucan. Int J Irnmunopharmacol 1987; 9: 261-7
19. Rasmussen LT, Seljelid R. Dynamics of blood components and peritoneal (luid during treatment of murine E. cnli sepsis with beta-1,3-D-polygfucose derivatives. 1. Cells. Scand J Immunol 1990; 32: 321-31
20. Hoffman OA, Oison EJ, Limper AH. Fungal -glucans modulate macrophage release of tumor necrosis tactor-ot in response to bacterial lipopolysaccharide. Immunol Lett 1993; 37: 19-25
21. Pretus HA, Browder IW, Lucore P, et al. Macrophage activation decreases macrophage prostaglandin E? release in experimental trauma. J Trauma 1989; 29: 1152-7
22. Williams DL, McNamee RB, Jones EL, et al. A method for the solubilization of a (l-3)-D-glucan isolated from Succharomyces ceivvisiae. Carbohydr Res 1991; 219: 203-13
23. 2.?. Marchessault RH. Deslandes Y. Fine structure of'il->3)-Dulucans: curdlan and parainylon. C'arhohydr Res 1979: 75: 2.11-42
24. Deslandes Y. Marchessault RH, Sarko A. Triple-helical structure of ( l-43)-D-ghican. Macromolecules 1980: 13: 1466-71
25. Bluhni TL. Deslandcs Y. Marchessault RH. el al. Solid-state and solution conformation ol scleroglucan. Carbohydr Res 1982: 100: 117-30
26. Williams DL, Sherwood ER. Brovvdcr 1W. el al. Effect ofglucan on neutrophil dynamics and Immune function in t-4chcrichiti coli peritonitis. J Surg Res 1988: 44: 54-61
27. Prctus HA. Ensley HE. McNamee RB. et al. Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan. J Pharmacol ExpTher 1991: 257 ( 1 ): 500-10
28. Mansell PWA. Ichinose H. Reed RJ. et al. Macrophage-medialed destruction of human malignant cells in rim. 1 Nail Cancer inst 1975:54(31:571-80
29. Williams DL. Sherwood ER. McNamee RB, et al. Therapeutic efficacy ofglucan in a nuirine model of hepatic metastatic disease. Hepatology 1985: 5: 198-206
30. Cook JA. Dougherty WJ, Holt TM. Enhanced sensitivity to endotoxin induced by the RE stimulant, lucan. Circ Shock 1980:7:225-38
31. Bowers GJ. Patchen Ml.. MacVittie TJ. et al. A comparative evaluation of paniculate and soluble glucan in an endotoxin model. Im J Immunopharniacol 1986: 8: 313-21
32. Rasiiiussen IT. Fandrem J. Seljelid R. Dynamics of blood components and peritoneal fluid during treatment of murine £. i-uli sepsis with beta-1.3-D-polyglucose derivatives. II. Inlerleukin I. tumour necrosis factor, proslaglandin E2. and leukolriene B4. Sound J Immunol 1990: 32: 333-40
33. Doita M. Rasmussen LT. Seljelid R. et al. Effect of soluble animated hela-l,3-D-polyglueose on human monocytes: stimulation of cytokine and prostaglandin E2 production but not antigen-presentini: function. J I.eukoc Biol 1991: 49: 342-51
34. Williams DL. Pretus HA. McNamee RB. et al. Development of a water-soluble, sulfaled ( l-3)-D-glucan biological response modifier derived from Snccliiimnm't'.\ ccreri-4iiic. Carbohydr Res 1992: 235: 247-57
35. Williams DL. Pretus HA. McNamee RB. et al. Development, physicochemical eharaeleriJ.ation and preelinieal efficacy evaluation ol a water soluble glucan sulfate derived from Siifflittt'(nnYci'\
36. Felippe .1. Sil\a M. Maciel EM. et al. Inleetion prevention in patients with severe multiple trauma w ith the immunomodulator beta 13 polyglucose (glucan). Sur Ciynecol Obstet 1993: 177: 3S.VX
37. Faisl E. Mew es A, Baker CC. el al. Proslaglandin E: (PGE:)depetulent suppression of interleukin alpha ( IE-2) production iu patients with major trauma. J Trauma 1987: 27: 837-48
38. Antrum KM. Solomkin JS. Monocyte dysfunction in severe trauma: e\idence for the nile of C5a in deactivation. Surgery 1986: 100: 29-37
39. Fite D. Kraus J. Infection as a contributory cause of death in patients hospitali/ed lor motor vehicle trauma. Am J Surg 1988; 15?: 278-82
40. Salmi LR, Williams J[. Waxweiler RJ. Measuring the impact of trauma care on survival: rates of preventable death, effectiveness, and efficacy. J Clin Epidemiol I9QO: 43: 399-403
41. C/op JK. Austen KF:. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte heta-glucan receptor. J Immunol 1985: 135: 33X8-93
42. C/op JK. Austen KF. Generation of leukotrienes hy human monocytes upon stimulation of their heta-glucan receptor during phagocytosis. Proc Natl Acad Sei USA 1985: 82: 2751-5
43. C/op JK. Austen KF. Beta-glucan inhihitable receptor on human monocytes: its identity with the phagocytic receptor for paniculate activators of the alternative complement pathway J Immunol 1985; 134: 2588-93
44. Goldman R. Induction of a beta-1.3-D-glucan receptor in P38XD1 cells treated with retinoic acid or 1.25-dihydroxyvilamin Di. Immunology 1988; 63: 319-24
45. C/op JK. Kav J. Isolation and characlcri/ation of -glucan receptors on human mononuclear phagocvtes. J Exp Med 1991: 173: 1511-20
46. Leibov ici J. Stark Y. Fldar T. et al. Mechanism of the inhibitory effect of levait on experimental tumors. Recent Results Cancer Res 1980: 75: 173-9
47. Williams JD. Topley N. Alohaidi HM, et al. Activation of human polymorphonuclear leucocytes by paniculate zymosan is related to both its major carbohydrate components: gluean and mannan. Immunology 1986; 58: 117-24
48. Janus/ MJ. Austen KF. C'/op JK. Isolation of a yeast heptaglucoside tor monocyte phagocytic -glucan receptors. FASFR J 1989:3:6421
49. Christ WJ. Asano O. Rohidoux ALC. et al. E5531. a pure endotoxin antagonist of high potency. Science 1995: 268: 80-3
50. Sherwood ER. Williams DL. Di Luzio NR. Gluean .stimulates production of amitumor cytolytic/eytostalic factor!s) bv macrophages. J Biol Response Mod 1986: 5: 504-26